SCHEDULE 13G 0001863769 XXXXXXXX LIVE Common Stock, $0.001 par value per share 12/09/2025 0001420720 iBio, Inc. 451033708 11750 Sorrento Valley Road, Suite 200 San Diego CA 92121 Rule 13d-1(c) Frazier Life Sciences Public Fund, L.P. b DE 0.00 1953467.00 0.00 1953467.00 1953467.00 8.7 PN The percentage listed in row 11 is calculated based on 22,487,308 shares of Common Stock outstanding on November 10, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on November 17, 2025. FHMLSP, L.P. b DE 0.00 1953467.00 0.00 1953467.00 1953467.00 8.7 PN The percentage listed in row 11 is calculated based on 22,487,308 shares of Common Stock outstanding on November 10, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on November 17, 2025. FHMLSP, L.L.C. b DE 0.00 1953467.00 0.00 1953467.00 1953467.00 8.7 OO The percentage listed in row 11 is calculated based on 22,487,308 shares of Common Stock outstanding on November 10, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on November 17, 2025. iBio, Inc. 11750 Sorrento Valley Road, Suite 200, San Diego, CA, 92121. The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304 The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference. Y The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 1,953,467 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. Except as specifically stated herein, the filing of this Schedule 13G shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G or a member of a "group" with any other person. The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement Frazier Life Sciences Public Fund, L.P. /s/ Steve R. Bailey 12/16/2025 FHMLSP, L.P. /s/ Steve R. Bailey 12/16/2025 FHMLSP, L.L.C. /s/ Steve R. Bailey 12/16/2025